These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 35777403)

  • 1. Equitable access to long-acting PrEP on the way?
    The Lancet Hiv
    Lancet HIV; 2022 Jul; 9(7):e449. PubMed ID: 35777403
    [No Abstract]   [Full Text] [Related]  

  • 2. Equitable access to PrEP is essential to reap its benefits.
    The Lancet Hiv
    Lancet HIV; 2023 Feb; 10(2):e69. PubMed ID: 36731987
    [No Abstract]   [Full Text] [Related]  

  • 3. Epidemiological impact and cost-effectiveness of providing long-acting pre-exposure prophylaxis to injectable contraceptive users for HIV prevention in South Africa: a modelling study.
    van Vliet MM; Hendrickson C; Nichols BE; Boucher CA; Peters RP; van de Vijver DA
    J Int AIDS Soc; 2019 Dec; 22(12):e25427. PubMed ID: 31855323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How much could long-acting PrEP cost in South Africa?
    Mudimu E; Bershteyn A
    Lancet HIV; 2022 Dec; 9(12):e814-e815. PubMed ID: 36356602
    [No Abstract]   [Full Text] [Related]  

  • 5. The importance of PrEP persistence in preventing HIV infections on PrEP.
    Spinelli MA; Laborde N; Kinley P; Whitacre R; Scott HM; Walker N; Liu AY; Gandhi M; Buchbinder SP
    J Int AIDS Soc; 2020 Aug; 23(8):e25578. PubMed ID: 32844591
    [No Abstract]   [Full Text] [Related]  

  • 6. The Potential of Long-Acting, Injectable PrEP, and Impediments to its Uptake.
    Miller AS; Krakower DS; Mayer KH
    J Urban Health; 2023 Feb; 100(1):212-214. PubMed ID: 36630070
    [No Abstract]   [Full Text] [Related]  

  • 7. Impact along the HIV pre-exposure prophylaxis "cascade of prevention" in western Kenya: a mathematical modelling study.
    Bershteyn A; Sharma M; Akullian AN; Peebles K; Sarkar S; Braithwaite RS; Mudimu E
    J Int AIDS Soc; 2020 Jun; 23 Suppl 3(Suppl 3):e25527. PubMed ID: 32602669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV Infection.
    Walensky RP; Jacobsen MM; Bekker LG; Parker RA; Wood R; Resch SC; Horstman NK; Freedberg KA; Paltiel AD
    J Infect Dis; 2016 May; 213(10):1523-31. PubMed ID: 26681778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-acting PrEP: new opportunities with some drawbacks.
    Xiridou M; Hoornenborg E
    Lancet HIV; 2023 Apr; 10(4):e213-e215. PubMed ID: 36642088
    [No Abstract]   [Full Text] [Related]  

  • 10. [HIV prevention with PrEP: Challenges and prospects].
    Guyonvarch O; Vaillant L; Hanslik T; Blanchon T; Rouveix E; Supervie V
    Rev Med Interne; 2021 Apr; 42(4):275-280. PubMed ID: 33127173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Has Pre-exposure Prophylaxis Made a Difference at a Population Level? Jury Is Still Out.
    Marcus JL; Paltiel AD; Walensky RP
    Clin Infect Dis; 2020 Dec; 71(12):3152-3153. PubMed ID: 32097454
    [No Abstract]   [Full Text] [Related]  

  • 12. [PrEP for HIV prevention, major tool of the global diversified prevention strategy].
    Slama L
    Rev Prat; 2021 Nov; 71(9):957-959. PubMed ID: 35147307
    [No Abstract]   [Full Text] [Related]  

  • 13. Nurse-led PrEP provision at 56 Dean Street.
    Whitlock G; Clark J; Tittle V;
    Lancet HIV; 2023 Feb; 10(2):e81. PubMed ID: 36563702
    [No Abstract]   [Full Text] [Related]  

  • 14. Long-Acting Injectable Preexposure Prophylaxis for HIV Prevention in South Africa: Is There a Will and a Way?
    Landovitz RJ; Grinsztejn B
    J Infect Dis; 2016 May; 213(10):1519-20. PubMed ID: 26681779
    [No Abstract]   [Full Text] [Related]  

  • 15. Expansion of PrEP and PEP services in China.
    Wang H; Tang W; Shang H
    Lancet HIV; 2022 Jul; 9(7):e455-e457. PubMed ID: 35688167
    [No Abstract]   [Full Text] [Related]  

  • 16. HIV PrEP and viral hepatitis: a unique opportunity for integration.
    Schaefer R; Schmidt HA; Rodolph M; Lesi O; Baggaley R; Luhmann N
    Lancet HIV; 2022 Nov; 9(11):e745. PubMed ID: 36332650
    [No Abstract]   [Full Text] [Related]  

  • 17. Engaging young women in Africa for PrEP use and adherence.
    Maharaj B; Karim QA
    Lancet HIV; 2021 Mar; 8(3):e122-e123. PubMed ID: 33662262
    [No Abstract]   [Full Text] [Related]  

  • 18. Awareness, knowledge, and attitudes related to HIV pre-exposure prophylaxis and other prevention strategies among physicians from Brazil and Mexico: cross-sectional web-based survey.
    Vega-Ramirez H; Torres TS; Guillen-Diaz C; Pimenta C; Diaz-Sosa D; Konda KA; da Cunha ARC; Robles-Garcia R; Benedetti M; Hoagland B; Bezerra DRB; Caceres CF; Grinsztejn B; Veloso VG;
    BMC Health Serv Res; 2022 Apr; 22(1):532. PubMed ID: 35459177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-exposure prophylaxis (PrEP) in an era of stalled HIV prevention: Can it change the game?
    Eakle R; Venter F; Rees H
    Retrovirology; 2018 Apr; 15(1):29. PubMed ID: 29609619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Awareness about and willingness to use long-acting injectable pre-exposure prophylaxis (LAI-PrEP) among people who use drugs.
    Shrestha R; DiDomizio EE; Kim RS; Altice FL; Wickersham JA; Copenhaver MM
    J Subst Abuse Treat; 2020 Oct; 117():108058. PubMed ID: 32811633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.